This clinical trial focuses on the management of moderate postoperative recurrence in Crohn’s disease. Crohn’s disease is a chronic inflammatory condition that affects the digestive tract. The study aims to evaluate the effectiveness of a treatment strategy called therapeutic escalation in patients who have experienced a recurrence of Crohn’s disease after surgery. The treatment being studied involves the use of a medication called infliximab, which is available in two forms: a 120 mg solution for injection in a pre-filled pen, known as Remsima, and a 100 mg powder for concentrate for solution for infusion, also known as Remsima. Infliximab is a type of protein that helps reduce inflammation in the body.

The purpose of the study is to determine how well patients respond to the treatment over a period of 12 months. Participants in the study will be divided into two groups. One group will receive the therapeutic escalation treatment with infliximab, while the other group will continue with their current treatment plan. The study will monitor the participants’ health and the recurrence of Crohn’s disease symptoms through regular check-ups and assessments. The goal is to see if the therapeutic escalation approach can help prevent further recurrence of the disease after surgery.

Throughout the study, participants will receive either the infliximab treatment or a placebo, and their progress will be closely monitored by healthcare professionals. The study will last for a total of 12 months, during which time the effectiveness of the treatment will be evaluated based on specific criteria. The results of this study may provide valuable insights into the management of Crohn’s disease and help improve treatment options for patients experiencing postoperative recurrence.